Green Cross to conduct phase 1 trial for MGAH22 in HER2-positive carcinoma
Developed by the U.S. based MacroGenics Inc., MGAH22 is a next-generation, Fc-optimized monoclonal antibody (mAb) that targets HER2. Based on an ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
